Lessons learned in migrating from one commercial genetics clinical decision-making tool to another: Assessment of data integrity and utilization

Calvin Le , Kevin Tatunay , Wayne Liu , Haibo Lu , Nicole-Ann Rodis , Thomas Nam , Mercy Y. Laurino , Marianne E. Dubard-Gault
{"title":"Lessons learned in migrating from one commercial genetics clinical decision-making tool to another: Assessment of data integrity and utilization","authors":"Calvin Le ,&nbsp;Kevin Tatunay ,&nbsp;Wayne Liu ,&nbsp;Haibo Lu ,&nbsp;Nicole-Ann Rodis ,&nbsp;Thomas Nam ,&nbsp;Mercy Y. Laurino ,&nbsp;Marianne E. Dubard-Gault","doi":"10.1016/j.gimo.2024.101913","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>Rapid advancements in information technology have greatly influenced clinicians’ engagement with patient data for health maintenance. The electronic health record often contains multiple ways to record risk factors and to identify patients at an elevated genetic risk for cancer. However, these variables exist in multiple forms and disparate locations in each commercial electronic health record solution resulting in significant variations in how family history or genetic data is codified. Furthermore, there is pressure to migrate from one commercial solution to another at times, prompting the need for a process ensuring data integrity during such a transition.</div></div><div><h3>Methods</h3><div>Between July and December 2023, the genetics team migrated a family history database from one commercial software solution to another. After the data migration of 13,000 patient records, we reviewed 500 randomly selected charts in both support tools to measure the rate of concordance of information transferred.</div></div><div><h3>Results</h3><div>A total of 461 patient charts were reviewed. Of these, 425 (92.2%) were noted to be concordant. Of the 36 charts that were discordant, 9 had incorrect genetic testing results entered, 19 had missing information, 5 charts contained data recorded on paper before 2017 (legacy data), and 3 had additional information transferred.</div></div><div><h3>Conclusion</h3><div>There was high data integrity after migration from one commercial software solution to another. Although these results can ease clinicians’ concerns after such support tool transitions, our effort also highlights areas for improvement in how family and patient genetic data are recorded and utilized for clinical care and research within an institution.</div></div>","PeriodicalId":100576,"journal":{"name":"Genetics in Medicine Open","volume":"3 ","pages":"Article 101913"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genetics in Medicine Open","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949774424010598","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose

Rapid advancements in information technology have greatly influenced clinicians’ engagement with patient data for health maintenance. The electronic health record often contains multiple ways to record risk factors and to identify patients at an elevated genetic risk for cancer. However, these variables exist in multiple forms and disparate locations in each commercial electronic health record solution resulting in significant variations in how family history or genetic data is codified. Furthermore, there is pressure to migrate from one commercial solution to another at times, prompting the need for a process ensuring data integrity during such a transition.

Methods

Between July and December 2023, the genetics team migrated a family history database from one commercial software solution to another. After the data migration of 13,000 patient records, we reviewed 500 randomly selected charts in both support tools to measure the rate of concordance of information transferred.

Results

A total of 461 patient charts were reviewed. Of these, 425 (92.2%) were noted to be concordant. Of the 36 charts that were discordant, 9 had incorrect genetic testing results entered, 19 had missing information, 5 charts contained data recorded on paper before 2017 (legacy data), and 3 had additional information transferred.

Conclusion

There was high data integrity after migration from one commercial software solution to another. Although these results can ease clinicians’ concerns after such support tool transitions, our effort also highlights areas for improvement in how family and patient genetic data are recorded and utilized for clinical care and research within an institution.
从一种商业遗传学临床决策工具迁移到另一种的经验教训:数据完整性和利用的评估
目的信息技术的快速发展极大地影响了临床医生对患者健康维护数据的参与。电子健康记录通常包含多种方式来记录风险因素和识别癌症遗传风险升高的患者。然而,这些变量在每个商业电子健康记录解决方案中以多种形式和不同的位置存在,导致家族史或遗传数据的编码方式存在重大差异。此外,有时存在从一个商业解决方案迁移到另一个解决方案的压力,这促使需要在这种转换期间确保数据完整性的流程。方法:在2023年7月至12月期间,遗传学团队将家族史数据库从一种商业软件解决方案迁移到另一种商业软件解决方案。在13000例患者记录的数据迁移之后,我们在两种支持工具中随机选择了500个图表,以测量信息传输的一致性。结果共回顾461例患者病历。其中425例(92.2%)被认为是一致的。在36个不一致的图表中,9个输入了不正确的基因检测结果,19个信息缺失,5个图表包含2017年之前纸质记录的数据(遗留数据),3个图表有额外的信息转移。结论从一个商业软件解决方案迁移到另一个商业软件解决方案后,数据完整性较高。虽然这些结果可以减轻临床医生在这种支持工具转换后的担忧,但我们的努力也强调了如何改进家庭和患者基因数据的记录和用于机构内的临床护理和研究的领域。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信